CoreWeave Rises, Cleveland Cliffs Gains, EyePoint Sinks to Record Low After Drug Trial Fails

On this episode of Stock Movers:

- CoreWeave (CRWV) shares rise. Goldman Sachs upgraded the cloud-computing provider to buy from neutral, a move that comes in the wake of heavy volatility related to concerns over the company’s debt.

- Cleveland Cliffs (CLF) shares gain as much as 20%, the most intraday since July, after the steel producer posted strong third quarter results helped by tariffs and strong prices.

- EyePoint (EYPT) shares plunge as much as 82% to hit a record low after the biotech’s experimental eye treatment, Duravyu, failed to achieve statistical non-inferiority in the Phase 3 LUCIA trial for wet AMD.

See omnystudio.com/listener for privacy information.